Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
10/10/2025 16:22
Oct 10 (Reuters) - Johnson & Johnson JNJ.N is in discussions to buy Protagonist Therapeutics PTGX.O, the Wall Street Journal reported on Friday, citing people familiar with the matter. Shares of Protagonist were up 9.4% in morning trade. (Reporting by Kamal Choudhury in Bengaluru; Editing by Anil D'Silva) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Protagonist Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary